ISCT revises cell and gene therapy forecast following FDA approval of Novartis CAR-T therapy
Following FDA approval of the Novartis CAR-T cell therapy CTL019, ISCT forecasts significant investment and funding throughout entire cell and gene therapy sector.
Please sign in or register for FREE
Sign in to RegMedNet
Register to RegMedNet
RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.